Literature DB >> 8642847

Characterization of acute lymphoblastic leukemia subtypes in Brazilian patients.

E M Rego1, A B Garcia, S R Viana, R P Falcão.   

Abstract

The distribution of the acute lymphoblastic leukemia (ALL) subsets in 225 consecutive Brazilian patients was determined by an immunophenotypic study with an extensive panel of monoclonal antibodies. All subsets were detected and their relative frequencies were similar to those described in developed countries, except for the B-mature subset which had a higher frequency, especially in adults. Associated myeloid markers were expressed by 11% of the ALL and CD10 by 15.9% of T-ALL cases. Besides, the incidence rates determined for the region of Ribeirão Preto showed that the overall incidence of ALL was 12.5 cases/10(6) people years (PY) (5 cases/10(6) PY in non-Whites versus 14 cases/10(6) PY in Whites); the incidence of childhood ALL was 25.5 cases/10(6) PY (8.1 versus 29.8 cases/10(6) PY in non-Whites and Whites, respectively) and the incidence of ALL in adults was 6.2 cases/10(6) PY (5.5 versus 6.1 cases/10(6) Py in non-Whites and Whites, respectively). The significantly lower incidence rate of ALL in non-White children was associated with a selective deficit of the common subtype and a lack of the typical age peak of incidence in this group. The ALL features demonstrated here in Brazilian non-White children resemble those described in the American non-Whites before the seventies and those in British and American Whites at the beginning of the century.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8642847     DOI: 10.1016/0145-2126(95)00147-6

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  1 in total

1.  Gamma-Delta T-Cell Acute Lymphoblastic Leukemia/Lymphoma: Immunophenotype of Three Adult Cases.

Authors:  Wei Wang; Yan Li; Min Ou-Yang; Meixiang Zhang; Linjun Zhao; Jianxin Liu; Yao Zhang; Wenqing Hu; Bin Jiang
Journal:  J Hematol (Brossard)       Date:  2019-09-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.